Haemonetics Corporation
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.33B | $1.36B | $1.31B | $1.17B | $993.2M | $870.5M | $988.5M | $967.6M |
| Cost of Revenue | $546.4M | $611.9M | $617.5M | $553.6M | $487.7M | $472.6M | $504.0M | $550.0M |
| Gross Profit | $787.6M | $749.0M | $691.5M | $615.1M | $505.5M | $397.8M | $484.5M | $417.5M |
| Gross Margin | 59.0% | 55.0% | 52.8% | 52.6% | 50.9% | 45.7% | 49.0% | 43.2% |
| Operating Expenses | ||||||||
| Research & Development | $59.8M | $62.7M | $54.4M | $50.1M | $46.8M | $32.9M | $30.9M | $35.7M |
| SG&A Expense | $442.4M | $436.8M | $429.8M | $376.7M | $340.1M | $275.2M | $282.0M | $273.5M |
| Operating Income | $156.7M | $221.8M | $164.9M | $156.0M | $80.8M | $89.7M | $103.4M | $83.5M |
| Operating Margin | 11.7% | 16.3% | 12.6% | 13.4% | 8.1% | 10.3% | 10.5% | 8.6% |
| Interest Expense | $19.3M | $35.9M | $19.5M | $13.0M | $5.8M | $9.4M | $13.5M | $12.6M |
| Pretax Income | $128.0M | $212.1M | $151.9M | $141.4M | $63.6M | $72.9M | $87.2M | $73.6M |
| Income Tax Expense | $30.7M | $44.4M | $34.3M | $26.0M | $20.3M | $-6.6M | $10.6M | $18.6M |
| Net Income | $97.3M | $167.7M | $117.6M | $115.4M | $43.4M | $79.5M | $76.5M | $55.0M |
| Net Margin | 7.3% | 12.3% | 9.0% | 9.9% | 4.4% | 9.1% | 7.7% | 5.7% |
| EPS (Basic) | $2.06 | $3.33 | $2.32 | $2.27 | $0.85 | $1.57 | $1.51 | $1.07 |
| EPS (Diluted) | $2.05 | $3.31 | $2.29 | $2.24 | $0.84 | $1.55 | $1.48 | $1.04 |
| Shares Outstanding (Basic) | 47.2M | 50.3M | 50.7M | 50.8M | 51.0M | 50.7M | 50.7M | 51.5M |
| Shares Outstanding (Diluted) | 47.4M | 50.7M | 51.4M | 51.4M | 51.4M | 51.3M | 51.8M | 52.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |